S1297 A Cohort Study of Association in Mortality Rates Between Proton Pump Inhibitor Usage and H2 Blocker Usage Among COVID-19 Patients

Abstract

Introduction: Mortality rates among patients who were hospitalized for COVID- 19 and were on Proton pump Inhibitors are compared to mortality rates among hospitalized COVID-19 patients and were on H2 blockers. Methods: Patients at two major urban hospitals in New Jersey were identified for the study. Patients who were COVID-19 positive and hospitalized and were put on either famotidine or Pantoprazole were enrolled for the study. Mortality rates were studied between these two cohort of patients and results are analyzed using chi-square method. Results: A total of 1243 patients who got admitted were identified. Of them 613 patients were tested COVID-19 negative and 630 patients were tested COVID-19 positive. Of the 630 patients who were COVID positive, patients were on either famotidine or pantoprazole, remaining 223 patients were not on either pantoprazole or famotidine. The patients were put on either pantoprazole or famotidine depending on their severity of illness and they were observed for mortality rates. A total of 262 patients were put on PPI and 145 patients were put on H2 blocker. A total of 147 patients expired and 260 patients were stabilized. Among PPI usage patients 106 patients expired and 156 were stabilized. Among H2 blocker users 41 patients expired and 104 patients were stabilized. A chi-square analysis of the results was done. The chi-square statistic is 6.0037, p-value is 0.014276. The result was significant as the p value was less than 0.05. Conclusion: The study shows that there is a significant association between PPI use and mortality among hospitalized COVID-19 patients. Patients who were on PPI usage during admission are associated with more mortality than the patients who put on H2 blockers.Figure 1.: Chi-Square Analysis.